(Q37909171)

English

First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study

scientific article published on 31 July 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

1 reference

based on heuristic

inferred from title

metastatic breast cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Norikazu Masuda

2

object named as

Norikazu Masuda

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

5

object named as

Hiroji Iwata

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

Yasuhiro Fujiwara

7

object named as

Yasuhiro Fujiwara

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

author name string

Kenjiro Aogi

1

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

Shinji Ohno

3

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

Takashi Oda

4

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

Masahiro Kashiwaba

6

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

Shunji Kamigaki

8

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

Yoshinori Ito

9

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

Takayuki Ueno

10

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

Shigemitsu Takashima

11

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

language of work or name

0 references

publication date

31 July 2011

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

129

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

829-838

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

https://scigraph.springernature.com/pub.10.1007/s10549-011-1685-x

0 references

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1685-X

21 January 2018

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1685-X

21 January 2018

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1685-X

21 January 2018

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1685-X

21 January 2018

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1685-X

21 January 2018

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1685-X

21 January 2018

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1685-X

21 January 2018

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1685-X

21 January 2018

Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1685-X

21 January 2018

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1685-X

21 January 2018

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1685-X

21 January 2018

Cytogenetic differences in breast cancer samples between German and Japanese patients.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1685-X

21 January 2018

Racial disparity in breast cancer and functional germ line mutation in galectin-3 (rs4644): a pilot study

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1685-X

21 January 2018

Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1685-X

21 January 2018

Iniparib plus chemotherapy in metastatic triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1685-X

21 January 2018

Platinum-based chemotherapy in triple-negative breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1685-X

21 January 2018

Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1685-X

21 January 2018

Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1685-X

21 January 2018

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1685-X

21 January 2018

Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1685-X

21 January 2018

Detecting an overall survival benefit that is derived from progression-free survival

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1685-X

21 January 2018

Congestive heart failure risk in patients with breast cancer treated with bevacizumab.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1685-X

21 January 2018

Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1685-X

21 January 2018

Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1685-X

21 January 2018

Identifiers

10.1007/S10549-011-1685-X

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37909171&oldid=2153526941"